Petros Pharmaceuticals, Inc.: additional paid-in capital

What this measure means

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Exact concept: us-gaap:AdditionalPaidInCapital. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.

Selected filing history

Related financial histories

• Petros Pharmaceuticals, Inc.: total assets
• Petros Pharmaceuticals, Inc.: total liabilities
• Petros Pharmaceuticals, Inc.: stockholders equity
• Petros Pharmaceuticals, Inc.: cash and cash equivalents
• Petros Pharmaceuticals, Inc.: net income or loss
• Petros Pharmaceuticals, Inc.: operating cash flow
• Petros Pharmaceuticals, Inc.: contract revenue excluding tax
• Petros Pharmaceuticals, Inc.: financing cash flow
• Petros Pharmaceuticals, Inc.: retained earnings or deficit
• Petros Pharmaceuticals, Inc.: basic weighted-average shares
• Petros Pharmaceuticals, Inc.: diluted weighted-average shares
• Petros Pharmaceuticals, Inc.: basic earnings per share
• Petros Pharmaceuticals, Inc.: diluted earnings per share
• Petros Pharmaceuticals, Inc.: income tax expense or benefit
• Petros Pharmaceuticals, Inc.: net property, plant and equipment
• Petros Pharmaceuticals, Inc.: share-based compensation expense
• Petros Pharmaceuticals, Inc.: operating income or loss
• Petros Pharmaceuticals, Inc.: current assets
• Petros Pharmaceuticals, Inc.: current liabilities
• Petros Pharmaceuticals, Inc.: current accounts payable
• Petros Pharmaceuticals, Inc.: net finite-lived intangible assets
• Petros Pharmaceuticals, Inc.: net current accounts receivable
• Petros Pharmaceuticals, Inc.: operating expenses
• Petros Pharmaceuticals, Inc.: net inventory
• Petros Pharmaceuticals, Inc.: gross profit
• Petros Pharmaceuticals, Inc.: selling, general and administrative expense
• Petros Pharmaceuticals, Inc.: research and development expense
• Petros Pharmaceuticals, Inc.: common shares outstanding
• Petros Pharmaceuticals, Inc.: cash including restricted cash
• Petros Pharmaceuticals, Inc.: operating lease right-of-use asset
• Petros Pharmaceuticals, Inc.: operating lease liability
• Petros Pharmaceuticals, Inc.: net intangible assets excluding goodwill
• Petros Pharmaceuticals, Inc.: other noncurrent liabilities
• Petros Pharmaceuticals, Inc.: accrued current liabilities
• Petros Pharmaceuticals, Inc.: prepaid expenses and other current assets
• Petros Pharmaceuticals, Inc.: pre-tax income or loss from continuing operations
• Petros Pharmaceuticals, Inc.: profit or loss including noncontrolling interests
• Petros Pharmaceuticals, Inc.: net income available to common stockholders
• Petros Pharmaceuticals, Inc.: depreciation, depletion and amortization
• Petros Pharmaceuticals, Inc.: amortization of intangible assets
• Petros Pharmaceuticals, Inc.: other nonoperating income or expense
• Petros Pharmaceuticals, Inc.: current income tax expense or benefit
• Petros Pharmaceuticals, Inc.: deferred income tax expense or benefit
• Petros Pharmaceuticals, Inc.: interest paid, net
• Petros Pharmaceuticals, Inc.: operating lease payments
• Petros Pharmaceuticals, Inc.: change in accounts receivable
• Petros Pharmaceuticals, Inc.: change in inventories
• Petros Pharmaceuticals, Inc.: change in accounts payable

Inspect the source

Entity

Petros Pharmaceuticals, Inc. / CIK 0001815903

Captured

2026-09-19T11:21:34.055Z

SEC response SHA-256

ce09757d7cf519fba34350164d20de41c934904fb0775c7180c184a51b39c633

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001815903.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))